Leerink Partnrs Raises Earnings Estimates for Kura Oncology

Kura Oncology, Inc. (NASDAQ:KURA) – Stock analysts at Leerink Partnrs increased their FY2024 EPS estimates for Kura Oncology in a research report issued on Thursday, November 21st. Leerink Partnrs analyst J. Chang now anticipates that the company will post earnings of ($2.19) per share for the year, up from their prior estimate of ($2.51). The consensus estimate for Kura Oncology’s current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Kura Oncology’s Q4 2024 earnings at ($0.39) EPS and FY2025 earnings at $0.70 EPS.

A number of other brokerages also recently commented on KURA. Lifesci Capital upgraded shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research note on Thursday, November 21st. Wedbush reissued an “outperform” rating and issued a $37.00 price target on shares of Kura Oncology in a research report on Monday, November 4th. UBS Group began coverage on shares of Kura Oncology in a research report on Thursday, October 24th. They issued a “buy” rating and a $27.00 price target for the company. Finally, Stifel Nicolaus cut shares of Kura Oncology from a “buy” rating to a “hold” rating and reduced their price target for the company from $26.00 to $19.00 in a research report on Monday, October 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.38.

Kura Oncology Stock Performance

Shares of KURA stock opened at $10.75 on Monday. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The firm has a fifty day moving average price of $17.68 and a 200 day moving average price of $19.60. The company has a market cap of $835.96 million, a P/E ratio of -4.56 and a beta of 0.86. Kura Oncology has a 12 month low of $9.06 and a 12 month high of $24.17.

Institutional Investors Weigh In On Kura Oncology

A number of institutional investors and hedge funds have recently made changes to their positions in KURA. Suvretta Capital Management LLC raised its holdings in shares of Kura Oncology by 8.2% in the third quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock valued at $149,535,000 after buying an additional 583,155 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Kura Oncology by 50.1% in the second quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock valued at $35,653,000 after buying an additional 577,732 shares during the last quarter. Sofinnova Investments Inc. raised its holdings in shares of Kura Oncology by 64.4% in the second quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock valued at $16,992,000 after buying an additional 323,303 shares during the last quarter. Armistice Capital LLC raised its holdings in shares of Kura Oncology by 14.7% in the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock valued at $48,386,000 after buying an additional 302,000 shares during the last quarter. Finally, Alethea Capital Management LLC raised its holdings in shares of Kura Oncology by 108.2% in the third quarter. Alethea Capital Management LLC now owns 553,542 shares of the company’s stock valued at $10,816,000 after buying an additional 287,636 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.